Department of Neurobiology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei 111, Taiwan.
School of Medicine, Fu Jen Catholic University, Xinzhuang Dist., New Taipei City 24205, Taiwan.
Int J Mol Sci. 2021 Jun 11;22(12):6306. doi: 10.3390/ijms22126306.
Previous studies have demonstrated that pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, inhibits ischemia-induced brain injury. The present study was conducted to examine whether pioglitazone can reduce impairment of behavioral deficits mediated by inflammatory-induced brain white matter injury in neonatal rats. Intraperitoneal (i.p.) injection of lipopolysaccharide (LPS, 2 mg/kg) was administered to Sprague-Dawley rat pups on postnatal day 5 (P5), and i.p. administration of pioglitazone (20 mg/kg) or vehicle was performed 5 min after LPS injection. Sensorimotor behavioral tests were performed 24 h after LPS exposure, and changes in biochemistry of the brain was examined after these tests. The results show that systemic LPS exposure resulted in impaired sensorimotor behavioral performance, reduction of oligodendrocytes and mitochondrial activity, and increases in lipid peroxidation and brain inflammation, as indicated by the increment of interleukin-1β (IL-1β) levels and number of activated microglia in the neonatal rat brain. Pioglitazone treatment significantly improved LPS-induced neurobehavioral and physiological disturbances including the loss of body weight, hypothermia, righting reflex, wire-hanging maneuver, negative geotaxis, and hind-limb suspension in neonatal rats. The neuroprotective effect of pioglitazone against the loss of oligodendrocytes and mitochondrial activity was associated with attenuation of LPS-induced increment of thiobarbituric acid reactive substances (TBARS) content, IL-1β levels and number of activated microglia in neonatal rats. Our results show that pioglitazone prevents neurobehavioral disturbances induced by systemic LPS exposure in neonatal rats, and its neuroprotective effects are associated with its impact on microglial activation, IL-1β induction, lipid peroxidation, oligodendrocyte production and mitochondrial activity.
先前的研究表明,吡格列酮是一种过氧化物酶体增殖物激活受体γ(PPARγ)激动剂,可抑制缺血性脑损伤。本研究旨在探讨吡格列酮是否可以减轻脂多糖(LPS,2mg/kg)腹腔注射诱导的新生大鼠脑白质损伤引起的行为缺陷。于新生后第 5 天(P5)给 Sprague-Dawley 幼鼠腹腔内(i.p.)注射 LPS(2mg/kg),LPS 注射后 5min 给予吡格列酮(20mg/kg)或载体腹腔内注射。LPS 暴露后 24h 进行感觉运动行为测试,并在这些测试后检查大脑的生化变化。结果表明,全身 LPS 暴露导致感觉运动行为表现受损、少突胶质细胞和线粒体活性减少,以及脂质过氧化和脑炎症增加,表现为新生大鼠脑内白细胞介素-1β(IL-1β)水平和活化小胶质细胞数量增加。吡格列酮治疗显著改善 LPS 诱导的神经行为和生理紊乱,包括新生大鼠体重减轻、体温降低、翻正反射、悬线操作、负趋地性和后肢悬停。吡格列酮对少突胶质细胞和线粒体活性丧失的神经保护作用与 LPS 诱导的硫代巴比妥酸反应物质(TBARS)含量、IL-1β水平和活化小胶质细胞数量增加的减弱有关。我们的结果表明,吡格列酮可预防新生大鼠全身 LPS 暴露引起的神经行为紊乱,其神经保护作用与其对小胶质细胞活化、IL-1β诱导、脂质过氧化、少突胶质细胞生成和线粒体活性的影响有关。